Tirzepatide Injection Pen
Tirzepatide is a once-weekly dual GIP/GLP‑1 agonist used to treat type 2 diabetes, promote weight loss, and support metabolic health.
Benefits
- Demonstrated significant reduction in HbA1c levels (~2.1–2.3 %)
- Promotes substantial weight loss (phase 3 trials show ~16–23 kg loss)
- Convenient once‑weekly injection
- Combines metabolic and glycemic control with appetite suppression
Mechanism of Action
Stimulates insulin secretion, inhibits glucagon, slows gastric emptying, and enhances satiety via dual incretin hormone pathways
Indications & Safety
- Approved for adults with type 2 diabetes, obesity, and moderate-to-severe OSA
- Common side effects: nausea, diarrhea, constipation, vomiting
- Not for type 1 diabetes or those with a personal/family history of medullary thyroid carcinoma or MEN 2
Storage & Handling
- Store refrigerated at 2–8 °C (36–46 °F)
- After first use, can be kept at room temperature per official guidelines
